Reading Hospital - McGlinn Cancer Institute — West Reading, Pennsylvania

Reading Hospital - McGlinn Cancer Institute is a clinical research site located in West Reading, Pennsylvania, United States 19611.

Crixeo Health Trust Score: 68/100 (FAIR). This profile has not yet been claimed by the site owner.

Reading Hospital - McGlinn Cancer Institute has participated in 5 clinical trials with 3 currently active.

Therapeutic areas: Primary Myelofibrosis, Myelodysplastic Syndromes, Leukemia, Myeloid, Acute.

Sponsors: Celgene, ImmunoVaccine Technologies, Inc. (IMV Inc.), Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.

Sponsor Feasibility Report

Trust Score: 68/100. Verification status: Not yet accredited. Patient reviews: 0. Complaints: 0.

Frequently Asked Questions

What is the Trust Score for Reading Hospital - McGlinn Cancer Institute?

Reading Hospital - McGlinn Cancer Institute has a Crixeo Trust Score of 68/100 (FAIR). Trust Scores reflect trial volume, sponsor diversity, patient reviews, address verification, and accreditation status.

How many clinical trials has Reading Hospital - McGlinn Cancer Institute conducted?

Reading Hospital - McGlinn Cancer Institute has 5 clinical trials on record, with 3 currently active. Their work covers Primary Myelofibrosis, Myelodysplastic Syndromes, Leukemia, Myeloid, Acute.

Is Reading Hospital - McGlinn Cancer Institute accredited by Crixeo Health?

Reading Hospital - McGlinn Cancer Institute has not yet obtained Crixeo Accreditation. Site owners can claim their profile and apply for accreditation to improve visibility with sponsors and patients.

Can I submit a review or complaint about Reading Hospital - McGlinn Cancer Institute?

Yes. Patients and trial participants can submit reviews and file complaints directly on this profile page. All submissions are reviewed before publication.